This site is intended only for Australian Healthcare Professionals
Choose your country
By clicking a link below you are choosing to leave the BioMarin Australia website; the country chosen is responsible for the content on that website.
Our products

KUVAN® (sapropterin dihydrochloride)

KUVAN® is indicated for the treatment of hyperphenylalaninemia (HPA) by reducing blood phenylalanine levels in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.

For Patients – Consumer Medicine Information

The Consumer Medicine Information (CMI) is a leaflet written for people who have been prescribed this product. This information is intended for use in Australia only and does not replace advice from a healthcare professional. You should discuss the CMI with your healthcare professional if you have any questions or concerns.

For Healthcare Professionals – Product Information

The Product Information (PI) is intended to assist healthcare professionals in making decisions about treatment and provide advice on the appropriate use of this product. This information is intended for use in Australia only.

For Registered Pharmacies and Hospitals Only – Place an Order

Patients and consumers should speak to their community pharmacy or prescriber for more information.

References:

  1. KUVAN Product Information, June 2023
  2. KUVAN Consumer Medicine Information, August 2021

Other products available in Australia

BRINEURA® (cerliponase alfa)

BRINEURA® is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

NAGLAZYME® (galsulfase (rch))

NAGLAZYME® is indicated for the treatment of Mucopolysaccharidosis VI (MPS VI) storage disorder, a disease in which the enzyme level of Nacetylgalactosamine 4-sulfatase is absent or lower than normal.

PALYNZIQ® (pegvaliase)

PALYNZIQ® is indicated for the treatment of patients with phenylketonuria (PKU) aged 16 and older, whose blood phenylalanine levels cannot be adequately controlled by other means such as by diet.

VIMIZIM® (elosulfase alfa (rch))

VIMIZIM® is indicated for the treatment of MPS IVA (Mucopolysaccharidosis Type IVA, Morquio A Syndrome).

VOXZOGO® (vosoritide)

VOXZOGO® is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.